Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain
Public ClinicalTrials.gov record NCT01001715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Vertebral Fracture Associated With Osteoporosis
Study identification
- NCT ID
- NCT01001715
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Interventions
- Placebo (for REGN475/SAR164877) Drug
- REGN475/SAR164877 Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2009
- Primary completion
- Dec 31, 2010
- Completion
- Dec 31, 2010
- Last update posted
- May 26, 2013
2009 – 2011
United States locations
- U.S. sites
- 11
- U.S. states
- 5
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sanofi-Aventis Investigational Site Number 840005 | Beverly Hills | California | 90211 | — |
| Sanofi-Aventis Investigational Site Number 840001 | Fresno | California | 93710 | — |
| Sanofi-Aventis Investigational Site Number 840017 | Sacramento | California | 95817 | — |
| Sanofi-Aventis Investigational Site Number 840028 | San Diego | California | 92103 | — |
| Sanofi-Aventis Investigational Site Number 840008 | Stockton | California | 95204 | — |
| Sanofi-Aventis Investigational Site Number 840013 | Boynton Beach | Florida | 33472 | — |
| Sanofi-Aventis Investigational Site Number 840047 | Clearwater | Florida | 33755 | — |
| Sanofi-Aventis Investigational Site Number 840034 | Atlanta | Georgia | 30328 | — |
| Sanofi-Aventis Investigational Site Number 840026 | New York | New York | 11201 | — |
| Sanofi-Aventis Investigational Site Number 840044 | Fort Worth | Texas | 76117 | — |
| Sanofi-Aventis Investigational Site Number 840023 | Southlake | Texas | 76092 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01001715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2013 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01001715 live on ClinicalTrials.gov.